SCHEMBL5453996

SCHEMBL5453996

N#Cc1ccc(-c2nc3ccncc3[nH]2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.66
KDM4E B2RXH2 3/20 0.66
PKM P14618 2/20 0.66
HPGD P15428 2/20 0.66
NPC1 O15118 1/20 0.66
RAB9A P51151 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
PKN1 Q16512 2/20 0.65
PKN2 Q16513 2/20 0.65
AURKA O14965 1/20 0.61
RHEB Q15382 1/20 0.57
HPSE Q9Y251 1/20 0.57
DGAT1 O75907 1/20 0.54
SOAT1 P35610 1/20 0.54
KCNH2 Q12809 1/20 0.54
MAPK14 Q16539 3/20 0.52
MAPK13 O15264 2/20 0.52
MAPK12 P53778 2/20 0.52
MAPK11 Q15759 2/20 0.52
RAF1 P04049 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23132141 0.88 PKN1 (0.61) ALDH1A1KDM4EPKMHPGDNPC1
Hydrochloric Acid SCHEMBL7271236 0.87 PKN1 (0.59) ALDH1A1KDM4EPKMHPGDNPC1
SCHEMBL30104576 0.80 ALDH1A1 (0.71) ALDH1A1KDM4EPKMHPGDNPC1
SCHEMBL21565901 0.80 ALDH1A1 (0.71) ALDH1A1KDM4EPKMHPGDNPC1
SCHEMBL7437914 0.80 ALDH1A1 (0.71) ALDH1A1KDM4EPKMHPGDNPC1
SCHEMBL3337258 0.80 NPC1 (0.66) ALDH1A1KDM4EPKMHPGDNPC1
SCHEMBL16331618 0.80 ALDH1A1 (0.71) ALDH1A1KDM4EPKMHPGDNPC1
SCHEMBL6245632 0.80 ALDH1A1 (0.71) ALDH1A1KDM4EPKMHPGDNPC1
SCHEMBL9694046 0.80 ALDH1A1 (1.00) ALDH1A1KDM4EPKMHPGDNPC1
SCHEMBL16332640 0.80 ALDH1A1 (1.00) ALDH1A1KDM4EPKMHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2026-03-17 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
EP-4110777-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) 2023-01-04 EP disclosed
CN-115175909-A Pyrrolopyridine and imidazopyridine antiviral compounds 鲁汶天主教大学 2022-10-11 CN disclosed
US-20070191420-A1 Kinase inhibitors DEVGEN NV 2007-08-16 US disclosed
EP-1715862-A1 KINASE INHIBITORS Devgen NV (BE) 2006-11-02 EP disclosed
WO-2005082367-A1 KINASE INHIBITORS DEVGEN NV (BE) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS SARS1, TPI1, TPMT ALDH1A1 1430/4885KDM4E 3519/4885PKM 124/4885
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds SARS1, TPMT, ZC3HAV1 ALDH1A1 3438/4885KDM4E 612/4885PKM 2288/4885
US-20070191420-A1 Kinase inhibitors ROCK1, ROCK2, MAP3K20 ALDH1A1 4377/4885KDM4E 569/4885PKM 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.